Can CSL Limited hit $100 per share?

Do shares in CSL Limited (ASX:CSL) look undervalued at the present time?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares in biotechnology company CSL Limited (ASX: CSL) briefly passed the $100 mark in August before declining by over 10% in-line with the wider market crash. Certainly, their fall of 4% in the last month alone is disappointing but, over the medium to long term they appear set to soar well past the $100 mark.

A key reason for this is the fact that CSL's profitability is less correlated with the wider economy than for most stocks. As such, the potential for a recession in Australia and the uncertainty which has gripped the global economy are unlikely to affect CSL to the same extent as for many of its index peers. For example, it continues to make excellent progress with the development of new treatments, while the integration of the recently acquired influenza business from Novartis for around $380m is also likely to boost earnings moving forward.

In addition, CSL generates the majority of its revenue from outside of Australia. This means that the falling interest rate and subsequently weaker Aussie dollar is good news for the business, since it equates to a boost in the company's bottom line. And, with growth prospects for the wider ASX being somewhat downbeat, investors may be willing to rerate upwards shares in CSL.

Clearly, CSL trades at a premium to the ASX, with it having a price to earnings (P/E) ratio of 22.8 versus 14.8 for the wider index. However, when CSL's earnings growth forecasts for an annualised increase in earnings over the next two years are taken into account, its price to earnings growth (PEG) ratio of 1.4 is in-line with that of the wider market. And, with CSL having a very stable track record of growing its bottom line (earnings have risen by almost 22% per annum during the last decade), it could be worth a larger premium to the wider index.

Furthermore, CSL is financially very sound. It has a debt to equity ratio of 83% and, in the last five years, has posted a rise in cash flow per share of almost 13% per annum. Despite this, it still pays out just 43% of earnings as a dividend which, when combined with its share price growth of 163% during the last five years, means that CSL yields just 2%. But, with dividends due to rise by 15% next year, it could become a much more appealing stock over the medium term, while the reinvestment of capital is aiding CSL's R&D and strengthening its product pipeline. Notably, CSL has new haemophilia treatments as well as opportunities within its specialties portfolio which should underpin growth in the coming years.

So, while the outlook for the ASX may be somewhat uncertain, CSL has the potential to soar past $100 per share owing to its growth potential, valuation and excellent business model. And, with a beta of just 0.6 its shares should offer a less volatile shareholder experience than the wider index on their way up to treble figures, too.

Motley Fool contributor Peter Stephens has no position in any stocks mentioned. Unless otherwise noted, the author does not have a position in any stocks mentioned by the author in the comments below. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »